Welcome to Trends-in-Medicine, offering independent, cutting-edge articles and information on drugs and devices in development. Our subscribers have access to news and analysis on the latest data, regulatory issues, and trends of interest to the healthcare community.

Quick Takes for March 16, 2025

ASCO-GI 2025

Here are some of the things we found interesting in the posters at ASCO-GI

Atrial Fibrillation Symposium

The key focus at this year's Atrial Fibrillation Symposium (AFS) was pulsed field ablation (PFA), though there were also talks on direct-acting anticoagulants, left atrial appendage (LAA) closure, weight loss drugs, and more

Virus Update

Here is a brief overview of the viruses that, right now, appear to be the most concerning: avian H5N1 bird flu, cholera, Covid-19, Marburg, measles (yes, that is still a threat), mpox (formerly monkeypox), and respiratory syncytial virus (RSV)

American Association for Cancer Research (AACR)

Among the multitude of drugs in early development with data at AACR were: AbbVie’s ABBV-303, a TriNKET for solid tumors; Bayer and Vividion Thera-peutics’ 225Ac-PSMA-Trillium, a radioligand for metastatic cancer; Pfizer’s PF-07220060, a CDK4 inhibitor for breast cancer; Revolution Medicines’ RMC-9805, a KRASG12D inhibitor for solid tumors; and Vividion Therapeutics and Roche’s VVD-214/RO-7589831, a WRN helicase inhibitor for MSI-high cancers. Other research of interest at AACR: Hunter BioDiscovery’s high throughput plat-form for discovering new combinations of existing drugs. And some regulatory insights from the National Cancer Institute director.

American Academy of Neurology

Among the interesting data on new drugs (and new uses for existing drugs) at AAN were treatments for Angelman syndrome, chronic infectious demyelinating polyneuropathy (CIDP), Devic disease (NMOSD), Huntington's disease (HD), migraine, multiple sclerosis.